T-cell engagers, including trispecific antibodies
中文As of 2026-11-01, Drugnews tracks 5 Asian programs in T-cell engagers, including trispecific antibodies across China, Japan, Korea and Taiwan; the most advanced is CM336 / OM336 from Keymed Biosciences Inc. (Phase 3).
Assets (5)
| Company | Country | Asset | Mechanism / format | Highest stage | Indication | Partner |
|---|---|---|---|---|---|---|
| Antengene Corporation Limited | China | ATG-201 | CD19 × CD3 bispecific T-cell engager | Phase 1 | B-cell-related autoimmune diseases | UCB |
| Suzhou Abogen Biosciences Co., Ltd. | China | ABO2203 | CD19 × CD3 bispecific T-cell engager | Phase 1 | Relapsed or refractory B-cell non-Hodgkin lymphoma | Novartis |
| Keymed Biosciences Inc. | China | CM336 / OM336 | BCMA × CD3 bispecific T-cell engager | Phase 3 | Relapsed or refractory multiple myeloma | — |
| China | CM350 | GPC3 × CD3 bispecific T-cell engager | Phase 1/2 | Advanced solid tumors | — | |
| Keymed Biosciences Inc.; InnoCare Pharma Limited | China | CM355 / ICP-B02 / PRO-203 | CD20 × CD3 bispecific T-cell engager | Phase 1/2 | Relapsed or refractory B-cell non-Hodgkin lymphoma | Prolium Biosciences, Inc. |
Asian outbound licensing (2)
| Date | Licensor | Country | Partner | Asset / portfolio | Territory | Upfront | Potential total |
|---|---|---|---|---|---|---|---|
| 2026-03-03 | Antengene Corporation Limited | China | UCB | ATG-201 and associated manufacturing technology | Worldwide | USD 60m | — |
| 2026-10-02 | Abogen Biosciences | China | Novartis | ABO2203 worldwide license and exclusive options to additional RNA-platform programs | Worldwide | USD 575m | — |
FAQ
How many Asian programs are tracked?
The 2026-11-01 table contains 5 programs in 4 originator groups.
Which program is the most advanced?
CM336 / OM336 from Keymed Biosciences Inc. is at Phase 3, the highest stage represented in this table.
Which companies and countries are represented?
Antengene Corporation Limited; Keymed Biosciences Inc.; Keymed Biosciences Inc.; InnoCare Pharma Limited; Suzhou Abogen Biosciences Co., Ltd.. Companies in this table originate from China.
Which drug formats are included?
bispecific T-cell engager. Stages and indications are listed separately for each program.
How are licensing deal values reported?
The table lists 2 outbound licensing events. Upfront payments and potential total values are separate, original currencies are retained, undisclosed amounts remain blank, and portfolio amounts are not allocated to individual assets.